Spero Therapeutics (SPRO) Releases Earnings Results, Beats Estimates By $0.15 EPS

Spero Therapeutics (NASDAQ:SPRO) issued its earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.15, Fidelity Earnings reports. Spero Therapeutics had a negative return on equity of 52.22% and a negative net margin of 1,402.91%. The company had revenue of $1.69 million for the quarter, compared to analyst estimates of $0.84 million.

Shares of NASDAQ:SPRO traded down $0.01 during trading on Friday, reaching $12.97. 22,979 shares of the stock were exchanged, compared to its average volume of 64,938. Spero Therapeutics has a 1-year low of $5.52 and a 1-year high of $19.00. The firm has a market capitalization of $223.16 million, a price-to-earnings ratio of -0.73 and a beta of 2.96.

SPRO has been the topic of a number of research reports. Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Saturday, January 5th. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research report on Sunday, January 13th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, February 26th. Finally, ValuEngine lowered Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Spero Therapeutics presently has an average rating of “Hold” and an average price target of $20.65.

A hedge fund recently raised its stake in Spero Therapeutics stock. Aquilo Capital Management LLC lifted its position in shares of Spero Therapeutics Inc (NASDAQ:SPRO) by 91.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 799,691 shares of the company’s stock after purchasing an additional 383,000 shares during the quarter. Spero Therapeutics accounts for 4.1% of Aquilo Capital Management LLC’s investment portfolio, making the stock its 8th largest holding. Aquilo Capital Management LLC owned 4.65% of Spero Therapeutics worth $8,405,000 at the end of the most recent quarter. Institutional investors own 51.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Spero Therapeutics (SPRO) Releases Earnings Results, Beats Estimates By $0.15 EPS” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://sportsperspectives.com/2019/03/15/spero-therapeutics-spro-releases-earnings-results-beats-estimates-by-0-15-eps.html.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

See Also: Diversification Important in Investing

Earnings History for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.